CoLucid Pharmaceuticals Inc. (NASDAQ:CLCD) reached a new 52-week high during mid-day trading on Tuesday . The company traded as high as $10.83 and last traded at $10.15, with a volume of 83,774 shares changing hands. The stock had previously closed at $9.49.

Separately, Zacks Investment Research downgraded shares of CoLucid Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Thursday, May 12th.

The firm’s market cap is $157.48 million. The firm’s 50-day moving average price is $8.87 and its 200 day moving average price is $7.26.

CoLucid Pharmaceuticals (NASDAQ:CLCD) last issued its quarterly earnings results on Wednesday, August 10th. The biopharmaceutical company reported ($1.06) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.84) by $0.22. Equities analysts predict that CoLucid Pharmaceuticals Inc. will post ($4.01) EPS for the current year.

In other CoLucid Pharmaceuticals news, major shareholder Domain Partners Vi, L.P. sold 153,028 shares of the company’s stock in a transaction dated Wednesday, August 3rd. The shares were sold at an average price of $8.45, for a total value of $1,293,086.60. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

CoLucid Pharmaceuticals, Inc is a Phase III clinical-stage biopharmaceutical company. The Company is engaged in developing a small molecule for the acute treatment of migraine headaches. Its product candidates address the needs of migraine patients, including those with cardiovascular risk factors or stable cardiovascular disease and those dissatisfied with existing therapies.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.